altimmune glp-1 Altimmune, Inc. Announces Presentation of IMPACT Phase 2b Study Results at EASL Congress 2026, Highlighting Efficacy and Safety Data for Pemvidutide in MASH FDA Grants Breakthrough Therapy Designation
Pay in 4 interest-free payments of $5.72 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5


























